缓解SARS-CoV-2传播影响的长期疫苗接种策略:一项模型研究
研究建立免疫-传播联合模型,模拟不同全球环境下的SARS-CoV-2传播与疫苗推广,量化未来加强针策略的影响。模型发现定期为75岁以上人群加强接种是高效策略,扩大至年轻年龄组可避免大量住院和死亡;在疫苗覆盖率低且感染诱导免疫高的国家,为老年高危人群加强接种比继续为年轻人群初种更有效。
要点
- 定期为75岁以上人群加强接种是高效策略,扩大至年轻组可减少住院和死亡。
- 疫苗覆盖率低且感染诱导免疫高的国家,加强老年高危组比年轻组初种更有效。
- 模型提示聚焦最高风险人群接种是降低发病和死亡的最有效且具成本效益的策略。
核心结论
- 模型提示定期为高危人群加强接种仍是减少当前和未来SARS-CoV-2变异株发病和死亡的重要工具。
- 结果提示聚焦最高风险人群接种将是降低发病和死亡的最有效且具成本效益的策略。
研究设计与样本
- 研究建立免疫-传播联合模型,参数化采用传播性、严重程度和疫苗有效性数据。
- 模拟不同人口年龄结构、接触模式、卫生系统能力、既往传播和疫苗 uptake 的典型全球环境下的SARS-CoV-2传播和疫苗推广。
主要发现
- 定期为最年长年龄组(75岁以上)加强接种是高效策略,但扩大接种至年轻年龄组可避免大量住院和死亡。
- 在疫苗覆盖率低且感染诱导免疫高的国家,模型显示为老年高危组加强接种比继续为年轻年龄组初种更有效。
局限性
- 研究受关键参数不确定性限制,包括疫苗和感染诱导免疫的长期持久性以及病毒未来进化的不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines have reduced severe disease and death from Coronavirus Disease 2019 (COVID-19). However, with evidence of waning efficacy coupled with continued evolution of the virus, health programmes need to evaluate the requirement for regular booster doses, considering their impact and cost-effectiveness in the face of ongoing transmission and substantial infection-induced immunity. METHODS AND FINDINGS: We developed a combined immunological-transmission model parameterised with data on transmissibility, severity, and vaccine effectiveness. We simulated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccine rollout in characteristic global settings with different population age-structures, contact patterns, health system capacities, prior transmission, and vaccine uptake. We quantified the impact of future vaccine booster dose strategies with both ancestral and variant-adapted vaccine products, while considering the potential future emergence of new variants with modified transmission, immune escape, and severity properties. We found that regular boosting of the oldest age group (75+) is an efficient strategy, although large numbers of hospitalisations and deaths could be averted by extending vaccination to younger age groups. In countries with low vaccine coverage and high infection-derived immunity, boosting older at-risk groups was more effective than continuing primary vaccination into younger ages in our model. Our study is limited by uncertainty in key parameters, including the long-term durability of vaccine and infection-induced immunity as well as uncertainty in the future evolution of the virus. CONCLUSIONS: Our modelling suggests that regular boosting of the high-risk population remains an important tool to reduce morbidity and mortality from current and future SARS-CoV-2 variants. Our results suggest that focusing vaccination in the highest-risk cohorts will be the most efficient (and hence cost-effective) strategy to reduce morbidity and mortality.
引用
- Hogan AB, Wu SL, Toor J, et al. Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study. PLoS Med. 2023. PMID: 38016000. doi:10.1371/journal.pmed.1004195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。